Enlivex Therapeutics Ltd. (ENLV)

NASDAQ: ENLV · IEX Real-Time Price · USD
3.790
-0.070 (-1.81%)
At close: Mar 28, 2024, 4:00 PM
3.750
-0.040 (-1.06%)
After-hours: Mar 28, 2024, 5:53 PM EDT

Company Description

Enlivex Therapeutics Ltd. operates as a clinical-stage macrophage reprogramming immunotherapy company.

It is developing Allocetra, a cell-based therapy to treat organ dysfunction and failure associated with sepsis that is in phase II clinical trial, as well as in preclinical trial to treat solid tumors.

The company has a collaboration agreement with BeiGene to evaluate the safety and efficacy of Allocetra in combination with tislelizumab, an anti-PD-1 immune checkpoint inhibitor for the treatment of patients with advanced-stage solid tumors.

Enlivex Therapeutics Ltd. is headquartered in Ness Ziona, Israel.

Enlivex Therapeutics Ltd.
Enlivex Therapeutics logo
Country Israel
Founded 2005
IPO Date Dec 12, 1995
Industry Biotechnology
Sector Healthcare
Employees 71
CEO Dr. Oren Hershkovitz Ph.D.

Contact Details

Address:
498 Seventh Avenue, Suite 1810
New York, New York 10018
United States
Phone 212-201-0800
Website enlivex.com

Stock Details

Ticker Symbol ENLV
Exchange NASDAQ
Fiscal Year January - December
Reporting Currency USD
CIK Code 0000919794
CUSIP Number M4130Y106
ISIN Number IL0011319527
Employer ID 95-4102687
SIC Code 7372

Key Executives

Name Position
Shai Novik M.B.A. Executive Chairman
Dr. Oren Hershkovitz Ph.D. Chief Executive Officer
Prof. Dror Mevorach M.D. Founder and Chief Scientific and Medical Officer
Shachar Shlosberger CPA Chief Financial Officer
Veronique Amor-Baroukh Senior Director of Operations
Sigal Arad Director of Human Resources

Latest SEC Filings

Date Type Title
Oct 3, 2008 15-12G Securities registration termination
Oct 3, 2008 8-K Current Report
Oct 2, 2008 25-NSE Filing
Sep 25, 2008 8-K Current Report
Sep 25, 2008 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Sep 9, 2008 DEFA14A Additional definitive proxy soliciting materials and Rule 14(a)(12) material
Sep 9, 2008 425 Filing
Sep 5, 2008 8-K Current Report
Sep 5, 2008 425 Filing
Aug 27, 2008 425 Filing